An ongoing clinical trial investigating the addition of tocilizumab, a monoclonal antibody against IL-6, alongside atezolizumab and fractionated stereotactic radiation therapy in recurrent GBM will shed more light on the clinical efficacy of concurrent IL-6 and PD-L1 blockade in GBM. Here, CD274 is linked to glioblastoma.